Want to see AU:CMB full AI Analyst Report?
Regeneus Ltd. (CMB) AI Stock Analysis
Regeneus Ltd.
(ASX:CMB)
The overall score is heavily pressured by the company's precarious financial state, characterized by minimal revenue, deep net losses, and significant cash burn, which are existential risks for a biotech firm. The lack of valuation support from negative earnings and no dividend further detracts from the score. The primary positive driver is the recent bullish technical momentum, with the stock trading above key moving averages, suggesting short-term market optimism that is disconnected from the fundamental reality.
Regeneus Ltd. (CMB) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 11.77M
- Dividend Yield
- ―
- Average Volume (3M)
- 9,182
- Price to Earnings (P/E)
- -1.6
- Beta (1Y)
- -0.01
- Revenue Growth
- -4.24%
- EPS Growth
- 33.39%
- Country
- Australia
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Regeneus Ltd. Business Overview & Revenue Model
Company Description
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. T...
Regeneus Ltd. Financial Statement Overview
Summary
Financial health is critically weak. The income statement shows a collapse in revenue and persistent, deep net losses exceeding $3.8M annually. Cash flow is a severe concern, with consistent and substantial operating cash burn. The only mitigating factor is a recently deleveraged balance sheet with low debt, but the small equity base is continuously eroded by losses.
Income Statement
18Very NegativeBalance Sheet
45NeutralCash Flow
12Very Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2023 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.33M | 641.64K | 670.06K | 0 | 719 | 7.07M |
| Gross Profit | 1.03M | 578.70K | 464.32K | -6,419 | 79.78K | 0 |
| EBITDA | -5.76M | -4.36M | -3.80M | -3.08M | -1.98M | 2.37M |
| Net Income | -5.62M | -4.10M | -3.84M | -3.38M | -2.26M | 2.76M |
Balance Sheet | ||||||
| Total Assets | 3.76M | 3.76M | 3.30M | 2.46M | 5.65M | 8.51M |
| Cash, Cash Equivalents and Short-Term Investments | 1.12M | 1.12M | 166.41K | 302.79K | 2.86M | 3.79M |
| Total Debt | 149.80K | 164.89K | 482.71K | 1.95M | 468.32K | 13.84K |
| Total Liabilities | 1.38M | 1.38M | 1.46M | 2.59M | 2.87M | 4.36M |
| Stockholders Equity | 2.38M | 2.38M | 1.84M | -1.81M | 2.78M | 4.15M |
Cash Flow | ||||||
| Free Cash Flow | -5.30M | -2.81M | -5.25M | -660.46K | -155.86K | 2.41M |
| Operating Cash Flow | -5.29M | -2.81M | -5.24M | -660.46K | -155.86K | 2.42M |
| Investing Cash Flow | -147.18K | -322.64K | -333.48K | -48.13K | -416.13K | -7,784 |
| Financing Cash Flow | 6.28M | 4.24M | 2.88M | 916.27K | 3.13M | 400.00K |
Regeneus Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CMB, the sentiment is Negative. The current price of 0.40 is below the 20-day moving average (MA) of 0.47, below the 50-day MA of 0.47, and below the 200-day MA of 0.46, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 22.57 is Positive, neither overbought nor oversold. The STOCH value of 25.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CMB.
Regeneus Ltd. Peers Comparison
Overall Rating
AU:MSB64Neutral
AU:OCC50Neutral- AU:CMB47Neutral
AU:CYP42Neutral
AU:1AI40Underperform
AU:TRP32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:MSB | 64Neutral | AUD 2.94B | -34.06 | -10.06% | ― | 555.67% | 49.08% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:OCC | 50Neutral | AUD 149.82M | -10.57 | -36.83% | ― | 51.07% | -47.63% |
| AU:CMB | 47Neutral | AUD 11.77M | -1.59 | -247.44% | ― | -4.24% | 33.39% |
| AU:CYP | 42Neutral | AUD 4.02M | -0.26 | -617.89% | ― | ― | 13.67% |
| AU:1AI | 40Underperform | AUD 20.28M | -5.71 | -132.20% | ― | ― | -200.00% |
| AU:TRP | 32Underperform | AUD 5.74M | -1.07 | -52.04% | ― | 32.22% | -26.53% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:CMB | Regeneus Ltd. | 0.40 | -0.09 | -19.19% | |
| AU:CYP | Cynata Therapeutics Limited | 0.01 | -0.23 | -95.40% | |
| AU:1AI | Living Cell Technologies Ltd. | 0.01 | 0.00 | 0.00% | |
| AU:MSB | Mesoblast Limited | 2.16 | -0.25 | -10.37% | |
| AU:OCC | Orthocell Ltd | 0.57 | -0.59 | -50.86% | |
| AU:TRP | Tissue Repair Ltd | 0.10 | -0.25 | -72.06% |
Regeneus Ltd. Corporate Events
Cambium Bio advances Elate Ocular Phase 3 program and shores up funding
Cambium Bio reported progress in both regulatory and manufacturing preparations for its pivotal Phase 3 CAMOMILE-2 trial of Elate Ocular, including submission of an updated protocol to the FDA and approvals from ethics committees in Australia and the...
Cambium Bio Sets Virtual 2026 AGM With Expert Report for Shareholders
Cambium Bio Limited has called shareholders to its 2026 Annual General Meeting, which will be held virtually on 9 November 2026 at 11:00am Sydney time via an online webcast platform. The company has released its Notice of Meeting on the ASX and its w...
Cambium Bio Calls Online AGM as Expert Backs Share Placement Plan
Cambium Bio Limited has convened its 2026 Annual General Meeting for 9 November, to be held entirely online via a dedicated meeting platform. Shareholders are invited to participate remotely or submit proxy forms, with the 2026 Annual Report availabl...
Cambium Bio Plans Major ASX Share Placement to Bolster Capital Base
Cambium Bio Limited has announced a proposed placement of ordinary fully paid shares on the ASX, reflecting its use of equity issuance as a key funding mechanism. The company is leveraging its listed status and disclosure framework to structure the o...
Cambium Bio sets online AGM date and director nomination deadline
Cambium Bio Limited has scheduled its 2026 Annual General Meeting to be held online on 9 November at 11:00 a.m. Sydney time, providing shareholders with digital access to attend, ask questions and vote. The company has set 2 October at 5:00 p.m. as t...
Cambium Bio Options Lapse, Trimming Potential Share Dilution
Cambium Bio Limited has notified the market of changes to its issued capital following the expiry of a tranche of options. The company remains listed on the ASX under the ticker CMB, with this announcement reflecting the routine management of its sec...
Cambium Bio Issues 160,000 Unquoted Options to Support Future Growth
Cambium Bio Limited has notified the market of the issuance of 160,000 unquoted options under the security code CMBAQ, with various exercise prices and expiry dates and an issue date of May 20, 2025. The additional unquoted options expand the company...
Cambium Bio locks in A$10.85m to fund Phase 3 dry eye trial
Cambium Bio has secured a total funding package of A$10.85 million to support its pivotal Phase 3 programme for Elate Ocular®, combining a A$7.1 million equity placement with a previously arranged A$3.75 million research and development tax ince...
Cambium Bio Plans New Share Placement to Bolster Capital Base
Cambium Bio Limited, trading on the ASX under the ticker CMB, is a biotechnology company developing biological products and leveraging public equity markets to support its growth. Its focus on securing capital underscores its status as an emerging pl...
Cambium Holdings Rectifies Late ASX Filings on Substantial Shareholder Changes
Cambium Holdings Limited has disclosed that notices of changes in interests for two substantial shareholders, Zheng Yang Biomedical Technology Co. Ltd. and Cyntec Co. Ltd., were lodged late with the ASX. The company attributes the delay, covering per...
Cambium Bio Corrects Option Expiry Date in ASX Securities Issue Filing
Cambium Bio Limited has updated its disclosure to the ASX regarding a proposed issue of securities, correcting the stated expiry date of certain options to 28 August 2031. The amendment, which relates to a prior announcement lodged on 1 September 202...
Cambium Bio Issues 2 Million Unquoted Options
Cambium Bio Limited has notified the market of the issue of 2,000,000 unquoted options under the ASX Appendix 3G framework. The options, carrying various exercise prices and expiry dates, were issued on 31 August 2026 and are not intended to be quote...
Cambium Bio Plans Issue of 2 Million Options in ASX Placement
Cambium Bio Limited has notified the ASX of a proposed issue of options as part of a placement or similar capital initiative. The company plans to issue up to 2,000,000 options with various expiry dates and exercise prices, with a proposed issue date...
Cambium Bio Files Updated Corporate Governance Statement and Appendix 4G
Cambium Bio Limited has lodged its updated corporate governance statement for the year ended 30 June 2026, confirming it is available on the company’s website and has been approved by the board as of 28 August 2026. The accompanying Appendix 4G...
Cambium Bio Narrows Annual Loss as Asset Backing Improves
Cambium Bio Limited reported revenue from ordinary activities of $642,000 for the year to 30 June 2026, down 4%, while other income jumped 334% to $596,000, narrowing its loss as net profit attributable to members came in at a $4.1 million loss, an i...
Cambium Bio Tightens Securities Trading Rules to Bolster Governance
Cambium Bio Limited has released an updated Securities Trading Policy outlining stricter rules for how key management personnel and employees may buy or sell company securities. The policy defines closed trading periods around financial reporting dat...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 23, 2026